Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study

January 2009
Journal of Teaching in Physical Education;Jan2009, Vol. 28 Issue 1, p341
Academic Journal
No abstract available.


Related Articles

  • Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study. Knapp, Martin; Windmeijer, Frank; Brown, Jacqueline; Kontodimas, Stathis; Tzivelekis, Spyridon; Haro, Josep Maria; Ratcliffe, Mark; Hong, Jihyung; Novick, Diego // PharmacoEconomics;2008, Vol. 26 Issue 4, p341 

    Objective: To determine the cost utility of treating schizophrenic patients with olanzapine compared with other antipsychotics in a naturalistic outpatient setting. Methods: The pan-European SOHO study is a 3-year, prospective, outpatient, observational study of outcomes associated with...

  • Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm. Cohen, Dan; De Hert, Marc // Neuropsychopharmacology;Oct2011, Vol. 36 Issue 11, p2368 

    The article focuses on the role of the drug olanzapine in the treatment of schizophrenia and its psychopharmacology. It talks on the complex relation of diabetes mellitus in patients with schizophrenia. It also discusses the twofold problem concerning the use of olanzapine which are lack of...

  • Risperidone: A Pharmacoeconomic Review of its Use in Schizophrenia. Foster, R.H.; Goa, K.L. // PharmacoEconomics;1998, Vol. 14 Issue 1, p97 

    The availability of new atypical antipsychotics, such as risperidone, that have higher acquisition costs than conventional treatments has prompted pharmacoeconomic evaluation of their costs and benefits. Risperidone is reported to have superior efficacy to haloperidol and similar efficacy to...

  • Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia. Attard, Azizah; Taylor, David M. // CNS Drugs;2012, Vol. 26 Issue 6, p491 

    Real-world, effectiveness studies add an important new dimension to the evaluation of the benefits of individual antipsychotics. Efficacy studies have already shown the unique effectiveness of clozapine, and suggested improved outcomes for olanzapine compared with some atypical antipsychotics...

  • Cost of antipsychotic polypharmacy in the treatment of schizophrenia. Zhu, Baojin; Ascher-Svanum, Haya; Faries, Douglas E.; Correll, Christoph U.; Kane, John M. // BMC Psychiatry;2008, Vol. 8, Special section p1 

    Background: This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics -- olanzapine, quetiapine, or risperidone. Methods: Data were drawn from a large, prospective, naturalistic, multi-site, nonrandomized...

  • Olanzapine probably most cost-effective antipsychotic in SOHO.  // PharmacoEconomics & Outcomes News;4/19/2008, Issue 551, p3 

    The article discusses research being done on olanzapine, an antipsychotic drug. It references a study by M. Knapp, F. Windmeijer et al published in a 2008 issue of "PharmaEconomics." According to the SOHO Study Group, olanzapine treatment has a high probability of being cost effective compared...

  • Olanzapine: An Updated Review of its Use in the Management of Schizophrenia. Bhana, N.; Foster, R.H.; Olney, R.; Plosker, G.L. // Drugs;Jan2001, Vol. 61 Issue 1, p111 

    Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. Compared with conventional antipsychotics, it has greater affinity for serotonin 5-HT than for dopamine D...

  • Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. Stauffer, Virginia; Karagianis, Jamie; Sutton, Virginia; Ascher-Svanum, Haya; Treuer, Tamas; de Lima, Mauricio Silva; Ball, Tamara; Poole-Hoffmann, Vicki; Tohen, Mauricio // Clinical Schizophrenia & Related Psychoses;Jul2008, Vol. 2 Issue 2, p136 

    Objective: All-cause discontinuation is considered a proxy for a medication's effectiveness. We examined the number needed to treat (NNT) to avoid all-cause medication discontinuation in head-to-head clinical trials of olanzapine versus other atypical antipsychotics. Methods: This was a post hoc...

  • Antipsychotic Use in the Older Patient With Schizophrenia. Khan, Sumera; Kasckow, John; Mulchahey, James L.; Mohamed, Somia // Behavioral Health Management;Mar/Apr2004, Vol. 24 Issue 2, pS1 

    Discusses several antipsychotic medications used in the treatment of older patients with schizophrenia. Clozapine; Risperidone; Olanzapine; Quetiapine.

  • Olanzapine: A Pharmacoeconomic Review of its Use in Schizophrenia. Foster, R.H.; Goa, K.L. // PharmacoEconomics;1999, Vol. 15 Issue 6, p611 

    Olanzapine is an atypical antipsychotic agent which is at least as effective as the conventional agent haloperidol and the atypical agent risperidone. Olanzapine may be superior to haloperidol in some respects, including treatment of negative symptoms. A major advantage of olanzapine over...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics